​

MacroGenics (MGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MGNX Stock Forecast

MacroGenics (MGNX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $2.00, with a high of $2.00 and a low of $2.00. This represents a 58.73% increase from the last price of $1.26.

- $4 $8 $12 $16 $20 High: $2 Avg: $2 Low: $2 Last Closed Price: $1.26

MGNX Stock Rating

MacroGenics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (47.62%), 10 Hold (47.62%), 1 Sell (4.76%), and 0 Strong Sell (0.00%).

Buy
Total 21 1 10 10 0 Strong Sell Sell Hold Buy Strong Buy

MGNX Price Target Upside V Benchmarks

TypeNameUpside
StockMacroGenics58.73%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts119
Avg Price Target$2.00$2.00$7.22
Last Closing Price$1.26$1.26$1.26
Upside/Downside58.73%58.73%473.02%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25126--9
Mar, 25127--10
Feb, 25137--11
Jan, 25137--11
Dec, 24237--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 25, 2025H.C. Wainwright$2.00$1.7911.73%58.73%
Aug 07, 2024Stephen WilleyStifel Nicolaus$6.00$3.3877.51%376.19%
Jul 31, 2024Silvan TuerkcanJMP Securities$8.00$5.2552.38%534.92%
Jul 31, 2024Mayank MamtaniB.Riley Financial$5.00$5.25-4.76%296.83%
Jul 29, 2024Peter LawsonBarclays$9.00$5.5562.16%614.29%
May 23, 2024Kaveri PohlmanBTIG$9.00$4.6394.38%614.29%
May 13, 2024Debjit ChattopadhyayH.C. Wainwright$4.00$4.38-8.68%217.46%
May 10, 2024Peter LawsonBarclays$14.00$14.67-4.57%1011.11%
May 10, 2024Etzer DaroutBMO Capital$8.00$14.67-45.47%534.92%
Apr 04, 2024Stephen WilleyStifel Nicolaus$29.00$13.67112.14%2201.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2024JMP SecuritiesMarket PerformMarket Performhold
Sep 18, 2024H.C. WainwrightNeutralNeutralhold
Sep 16, 2024Cowen & Co.HoldHoldhold
Aug 21, 2024H.C. WainwrightNeutralNeutralhold
Aug 15, 2024JMP SecuritiesMarket PerformMarket Performhold
Jul 31, 2024BTIGBuyNeutraldowngrade
Jul 31, 2024JMP SecuritiesOutperformOutperformhold
Jul 31, 2024GuggenheimAccumulateNeutraldowngrade
Jul 31, 2024B. RileyNeutraldowngrade
Jul 31, 2024GuggenheimUnderperformAccumulatedowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.25$-3.18$-1.95$-0.15$-1.07----
Avg Forecast$-3.20$-3.25$-2.03$0.43$-1.20$-2.20$-1.87$-2.31$-2.32
High Forecast$-1.57$-1.59$-0.80$0.49$-1.02$-0.48$-0.55$-1.70$-0.16
Low Forecast$-4.97$-5.05$-3.38$0.29$-1.40$-3.47$-3.30$-2.92$-5.50
Surprise %-29.69%-2.15%-3.94%-134.88%-10.83%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$97.76M$75.64M$151.94M$58.75M$149.96M----
Avg Forecast$76.67M$83.89M$150.06M$80.88M$159.93M$77.97M$87.38M$76.42M$120.09M
High Forecast$109.33M$119.63M$226.35M$92.31M$172.05M$131.38M$88.48M$156.83M$246.44M
Low Forecast$46.57M$50.95M$79.99M$68.52M$144.41M$18.14M$86.27M$21.65M$34.02M
Surprise %27.51%-9.83%1.26%-27.37%-6.23%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.78M$-190.86M$-120.02M$-9.06M$-66.97M----
Avg Forecast$-145.55M$-145.85M$-195.63M$49.82M$-74.81M$-176.54M$-164.31M$-143.21M$-143.88M
High Forecast$-116.44M$-116.68M$-156.51M$59.78M$-62.92M$-29.78M$-34.34M$-105.55M$-9.83M
Low Forecast$-174.66M$-175.02M$-234.76M$39.85M$-86.70M$-215.05M$-204.28M$-180.87M$-340.67M
Surprise %-19.08%30.86%-38.65%-118.18%-10.49%----

MGNX Forecast FAQ

Is MacroGenics stock a buy?

MacroGenics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that MacroGenics is a favorable investment for most analysts.

What is MacroGenics's price target?

MacroGenics's price target, set by 21 Wall Street analysts, averages $2 over the next 12 months. The price target range spans from $2 at the low end to $2 at the high end, suggesting a potential 58.73% change from the previous closing price of $1.26.

How does MacroGenics stock forecast compare to its benchmarks?

MacroGenics's stock forecast shows a 58.73% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for MacroGenics over the past three months?

  • April 2025: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 10.00% Strong Buy, 20.00% Buy, 70.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 9.09% Strong Buy, 27.27% Buy, 63.64% Hold, 0% Sell, 0% Strong Sell.

What is MacroGenics’s EPS forecast?

MacroGenics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.2, marking a 105.61% increase from the reported $-1.07 in 2024. Estimates for the following years are $-1.87 in 2026, $-2.31 in 2027, and $-2.32 in 2028.

What is MacroGenics’s revenue forecast?

MacroGenics's average annual revenue forecast for its fiscal year ending in December 2025 is $77.97M, reflecting a -48.00% decrease from the reported $149.96M in 2024. The forecast for 2026 is $87.38M, followed by $76.42M for 2027, and $120.09M for 2028.

What is MacroGenics’s net income forecast?

MacroGenics's net income forecast for the fiscal year ending in December 2025 stands at $-177M, representing an 163.63% increase from the reported $-66.966M in 2024. Projections indicate $-164M in 2026, $-143M in 2027, and $-144M in 2028.